Skip to main content
. 2022 Dec 20;7(1):e811. doi: 10.1097/HS9.0000000000000811

Table 1.

Seropositivity Rates Post Initial Vaccine Series Reported for Patients With CLL or Other Hematologic Malignancies

Author Patients With CLL Other Hematologic Malignancies
N Response (%) Disease Type, n Response (%)
Giuliano et al (2022)25 23 65.2 HL, 10 100
AML, 30 100
MDS, MPN, or MDS/MPN, 49 85.7
B-cell NHL, 55 58.2
MM, 88
Other, <20 patients eacha 		93.2
Teh et al (2021)21 1446 51 AML/MDS, 126 93
MPN/CML, 281 87–88
Myeloma, 1218 76–80
Lymphoma, 1296 52–55
Gagelmann et al (2021)20 1753 50 HL, 133 91
MPN, 365 83
Aggressive NHL, 386 58
Indolent NHL, 494 61
Myeloma, 1564 76
Gong et al (2022)26 1709 44 PCD, 2066 72
Lymphoid malignancies, 1904 52
MPN, 464 81
Acute leukemias, 147 83
MDS, 79 63
Šušol et al (2022)24 53 39.6 HL, 21 76.2
aNHL, 32 37.5
iNHL, 62 54.8
MM, 119 87.4
AL/MDS, 33 84.8
cMPN, 54 92.6
Shen et al (2021)27 160 55 MBL, 21 90.5
Greenberger et al (2021)28 650 64.2 MCL, 27 44.4
Smoldering MM, 29 100
AML, 34 91.2
CML, 34 97.1
MZL, 34 61.8
MDS/MPN, 35 97.1
NHL NOS, 48 79.2
DLBCL, 52 78.8
HL, 65 98.5
WM, 97 74.2
FL, 98 77.6
MM, 184 95.1
Other, <20 patients eacha
Herzog Tzarfati et al (2021)29 34 47 CML, 22 91
Indolent NHL, 40 60
Aggressive NHL, 51 71
MM, 53 76
MPN, 68 84
Dong et al (2021)30 23 65.2 B-cell NHL, 55 Other, <20 patients eacha 58.2
Molica et al (2022)31 2082 52
Bagacean et al (2022)32 506 52
Molica et al (2022)33 70 58.5
Bergman et al (2021)34 79 63.3
Sun et al (2021)35 58 60.3
Parry et al (2022)36 500 67
Benjamini et al (2022)37 373 43
Roeker et al (2021)38 44 52
Tadmor et al (2021)39 84 58.3
Herishanu et al (2021)40 167 39.5
Ujjani et al (2022)23 37 41
Haydu et al (2022)41 36 55.6

aResponse rates only reported for hematologic malignancies where the reference cites results for .20 patients.

ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CLL = chronic lymphocyticleukemia; CML = chronic myeloid leukemia; CMPN = chronic myeloproliferative neoplasm; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; HL = Hodgkin lymphoma; MBL = monoclonal B-lymphocytosis; MDS = myelodysplastic syndromes; MM = multiple myeloma; MPN = myeloproliferative neoplasm; n = number of patients; NHL = non-Hodgkin lymphoma; NK = natural killer.